AB-1015

Arsenal Biosciences, Inc. · Phase 1 active Biologic

At a glance

Generic name	AB-1015
Also known as	Integrated Circuit T (ICT) cells
Sponsor	Arsenal Biosciences, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AB-1015 CI brief — competitive landscape report
AB-1015 updates RSS · CI watch RSS
Arsenal Biosciences, Inc. portfolio CI